See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $111B | 9.3x | 21.1x | |
| $10.9B | 3.4x | 14.1x | |
| $6.3B | 16.3x | 37.9x | |
| $4.6B | 7.3x | 43.8x | |
| $4.2B | 1235.0x | -258.3x | |
| $3.6B | 406.0x | -6.5x | |
| $2.5B | 38.8x | -75.2x | |
| $2.3B | 6.3x | 14.5x | |
| $1.8B | 6.5x | 25.6x | |
| $1.8B | 46.4x | -3.7x | |
| $1.5B | 6.8x | 54.3x | |
| $1.5B | n/a | n/a | |
| $1.4B | 1093.7x | -14.0x | |
| $922M | 2.3x | 9.2x | |
| $864M | 53.7x | -5.0x | |
| $819M | 1.6x | 14.1x | |
| $779M | n/a | -30.2x | |
| $657M | 11.6x | -1.5x | |
| $590M | 13.4x | 108.9x | |
| $450M | 13.8x | 31.1x | |
| $349M | 35.3x | -9.8x | |
| $286M | 254.2x | n/a | |
| $242M | n/a | n/a | |
| $226M | n/a | n/a | |
| $218M | 79.1x | n/a | |
| $174M | 22.7x | -31.2x | |
| $154M | 5.8x | 17.0x | |
| $152M | n/a | -0.7x | |
| $152M | 2.7x | 41.9x | |
| $108M | n/a | n/a | |
| $105M | 0.9x | 51.2x | |
| $105M | n/a | n/a | |
| $68.2M | n/a | n/a | |
| $65.1M | 129.9x | -0.4x | |
| $50.7M | n/a | n/a | |
| $50.6M | n/a | -4.1x | |
| $49.7M | 2.6x | -5.5x | |
| $47.3M | 0.2x | n/a | |
| $46.8M | 517.7x | n/a | |
| $40.1M | 13.7x | -6.1x | |
| $31.4M | n/a | n/a | |
| $19.1M | n/a | n/a | |
| $15.7M | 1.1x | n/a | |
| $13.3M | 3.1x | n/a | |
| $3.5M | 3.4x | n/a | |
| -$64.7M | -0.7x | 0.4x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine